Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders

Cells, Год журнала: 2024, Номер 13(6), С. 511 - 511

Опубликована: Март 14, 2024

Neuroinflammatory and neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s (PD), traumatic brain injury (TBI) Amyotrophic lateral sclerosis (ALS) are chronic major health disorders. The exact mechanism of the neuroimmune dysfunctions these pathogeneses is currently not clearly understood. These show dysregulated inflammatory responses, activation neurons, glial cells, neurovascular unit damage associated with excessive release proinflammatory cytokines, chemokines, neurotoxic mediators, infiltration peripheral immune cells into brain, as well entry mediators through damaged endothelial blood–brain barrier tight junction proteins. Activation leads to many molecules that cause neuroinflammation neurodegeneration. Gulf War Illness (GWI) myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) also dysfunctions. Currently, there no effective disease-modifying therapeutic options available for diseases. Human induced pluripotent stem cell (iPSC)-derived astrocytes, microglia, pericytes used models drug discovery. This review highlights certain recent trends in neuroinflammatory responses iPSC-derived applications

Язык: Английский

---

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(20), С. 12289 - 12289

Опубликована: Окт. 14, 2022

The bidirectional interaction between the gut microbiota (GM) and Central Nervous System, so-called brain axis (GMBA), deeply affects function has an important impact on development of neurodegenerative diseases. In Parkinson’s disease (PD), gastrointestinal symptoms often precede onset motor non-motor manifestations, alterations in GM composition accompany pathogenesis. Several studies have been conducted to unravel role dysbiosis intestinal permeability PD progression, but therapeutic diagnostic applications modifying approaches remain be fully elucidated. After a brief introduction involvement GMBA disease, we present evidence for leaky patients. According these data, then review potential GM-based signatures serve as biomarkers highlight emerging probiotics, prebiotics, antibiotics, dietary interventions, fecal transplantation supportive PD. Finally, analyze mutual influence commonly prescribed medications gut-microbiota, offer insights also nasal oral pathology, thus providing comprehensive up-to-date overview microbial features diagnosis treatment.

Язык: Английский

---

Heme oxygenase‐1: The roles of both good and evil in neurodegenerative diseases

Journal of Neurochemistry, Год журнала: 2023, Номер 167(3), С. 347 - 361

Опубликована: Сен. 25, 2023

Abstract Heme oxygenase‐1 (HO‐1) is the only way for cells to decompose heme. It can cleave heme produce carbon monoxide (CO), ferrous iron (Fe 2+ ), and biliverdin (BV). BV reduced bilirubin (BR) by reductase(BVR). In previous studies, HO‐1 was considered have protective effects because of its anti‐inflammatory, anti‐apoptosis, antiproliferation functions. However, emerging experimental studies found that metabolites derived from cause increase iin intracellular oxidative stress, mitochondrial damage, death, autophagy. Because particularity, it very meaningful understand exact mechanism. this review, we summarized toxic HO‐1, potential mechanism, role in neurodegenerative diseases related drug research. This knowledge may be beneficial development new therapies crucial therapeutic strategies biomarkers. image

Язык: Английский

---

Levodopa-loaded nanoparticles for the treatment of Parkinson's disease

Journal of Controlled Release, Год журнала: 2023, Номер 360, С. 212 - 224

Опубликована: Июнь 25, 2023

Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) resulting dopamine (DA) deficiency, which manifests itself motor symptoms including tremors, rigidity and bradykinesia. Current PD treatments aim at symptom reduction through oral delivery levodopa (L-DOPA), precursor DA. However, L-DOPA to brain inefficient increased dosages are required as progresses, serious side effects like dyskinesias. To improve treatment efficacy reduce effects, recent research focuses on encapsulation into polymeric- lipid-based nanoparticles (NPs). These formulations can protect from systemic decarboxylation DA central nervous system. Additionally, NPs be modified with proteins, peptides antibodies specifically targeting blood-brain barrier (BBB), thereby reducing free Alternative approaches for NP-encapsulated include intravenous (IV) administration, transdermal using adhesive patches direct intranasal facilitating therapeutic concentrations brain. This review provides an overview advances NP-mediated brain, debates challenges future perspectives field.

Язык: Английский

---

Role of histone modifications in neurogenesis and neurodegenerative disease development

Ageing Research Reviews, Год журнала: 2024, Номер 98, С. 102324 - 102324

Опубликована: Май 16, 2024

Язык: Английский

---

The rise of Parkinson’s disease is a global challenge, but efforts to tackle this must begin at a national level: a protocol for national digital screening and “eat, move, sleep” lifestyle interventions to prevent or slow the rise of non-communicable diseases in Thailand

Frontiers in Neurology, Год журнала: 2024, Номер 15

Опубликована: Май 13, 2024

The rising prevalence of Parkinson’s disease (PD) globally presents a significant public health challenge for national healthcare systems, particularly in low-to-middle income countries, such as Thailand, which may have insufficient resources to meet these escalating needs. There are also many undiagnosed cases early-stage PD, period when therapeutic interventions would the most value and least cost. traditional “passive” approach, whereby clinicians wait patients with symptomatic PD seek treatment, is inadequate. Proactive, early identification will allow timely interventions, digital technologies can be scaled up diagnosis cases. risk survey (TCTR20231025005) aims evaluate population screening platform identify Thai population. Recognizing long prodromal phase target demographic people aged ≥ 40 years, approximately 20 years before usual emergence motor symptoms. Thailand has highly rated system an established universal program citizens, making it ideal deploying using technology. Designed by multidisciplinary group experts, comprises 20-item questionnaire about symptoms along objective tests eight markers: voice vowel, sentences, resting postural tremor, alternate finger tapping, “pinch-to-size” test, gait balance, performance recorded mobile application smartphone’s sensors. Machine learning tools use collected data subjects at developing, or signs of, PD. This article describes selection validation items markers, results showing chosen parameters analysis methods robust, reliable, reproducible. could serve model similar strategies other non-communicable diseases Thailand.

Язык: Английский

---

Bifidobacterium infantis and Bifidobacterium breve Improve Symptomatology and Neuronal Damage in Neurodegenerative Disease: A Systematic Review

Nutrients, Год журнала: 2025, Номер 17(3), С. 391 - 391

Опубликована: Янв. 22, 2025

Background/Objectives: This systematic review focused on collecting the most significant findings impact of administration Bifidobacterium infantis (or longum subps. infantis) and breve, alone, in conjunction, or combination with other strains, treatment neurodegenerative diseases including Alzheimer’s disease (AD) Parkinson’s (PD). These are characterized by progressive degeneration neurons, resulting a broad spectrum clinical manifestations. AD is typified decline cognitive abilities, while PD marked motor symptoms associated loss dopamine (DA). Methods: Five different databases, ScienceDirect, Scopus, Wiley, PubMed, Web Science (WoS), were reviewed studies screened for inclusion following criteria: (i) that specifically evaluated use infantis, subsp. breve as therapeutic intervention, either human animal models, context diseases; (ii) required to address one more pathologies examined this article, included, but not limited to, neurodegeneration, disease, oxidative stress; (iii) full text was accessible online; (iv) article written English. Results: The data suggest these probiotics have neuroprotective effects may delay progression. Conclusions: study provides updated insights into strains like PD, main limitation being number trials available.

Язык: Английский

---

Expression levels of protein inhibitor of activated STAT (PIAS) family genes in Parkinson’s disease patients: results from a case-control study

Acta Neurologica Belgica, Год журнала: 2025, Номер unknown

Опубликована: Фев. 28, 2025

Язык: Английский

---

Ubiquitin Carboxyl-Terminal Hydrolase L1 and Its Role in Parkinson’s Disease

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 1303 - 1303

Опубликована: Янв. 21, 2024

Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), also known as Parkinson’s disease protein 5, is a highly expressed in the brain. It plays an important role ubiquitin–proteasome system (UPS), where it acts deubiquitinase (DUB) enzyme. Being smallest member of UCH family DUBs, catalyzes reaction ubiquitin precursor processing and cleavage ubiquitinated remnants, thus maintaining level monomers brain cells. UCHL1 mutants, containing amino acid substitutions, influence catalytic activity its aggregability. Some them protect cells transgenic mice toxin-induced (PD) models. Studies putative partners revealed about sixty individual proteins located all major compartments cell: nucleus, cytoplasm, endoplasmic reticulum, plasma membrane, mitochondria, peroxisomes. These include related to development PD, such alpha-synuclein, amyloid-beta protein, ubiquitin-protein ligase parkin, heat shock proteins. In context paradigm, importance these interactions not clear. However, there increasing understanding that exhibits various effects catalytically independent manner through protein–protein interactions. Since this represents up 5% soluble brain, PD-related changes structure will have profound on proteomes/interactomes which involved. Growing evidence accumulating PD obviously determined by balance canonic numerous activity-independent interactions, still need better characterization.

Язык: Английский

---

Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?

Pharmaceutics, Год журнала: 2024, Номер 16(6), С. 708 - 708

Опубликована: Май 24, 2024

Neurodegenerative diseases (NDs) are a set of progressive, chronic, and incurable characterized by the gradual loss neurons, culminating in decline cognitive and/or motor functions. Alzheimer’s disease (AD) Parkinson’s (PD) most common NDs represent an enormous burden both terms human suffering economic cost. The available therapies for AD PD only provide symptomatic palliative relief limited period unable to modify diseases’ progression. Over last decades, research efforts have been focused on developing new pharmacological treatments these NDs. However, date, no breakthrough treatment has discovered. Hence, development disease-modifying drugs able halt or reverse progression remains unmet clinical need. This review summarizes major hallmarks treatment. It also sheds light potential directions that can be pursued develop new, treat PD, describing as representative examples some advances drug candidates targeting oxidative stress adenosine A2A receptors.

Язык: Английский

---